Meet Neuland at CPHI India 2026 | Hall 2, Booth 2D38 | Yashobhoomi Convention Centre, New Delhi | 24-26 November 2026 Schedule a Meeting
Meet Neuland at CPHI India 2026 | Hall 2, Booth 2D38 | Yashobhoomi Convention Centre, New Delhi | 24-26 November 2026 Schedule a Meeting
Continuous flow manufacturing for APIs makes a drug substance on one connected line, with no pauses between steps. Because material keeps moving, this approach can shorten production time and make hazardous reactions safer to run.
Yet most API producers have stayed with batch processing, partly because regulators lacked shared rules for continuous processes. In November 2022, ICH Q13 gave regulators such as the FDA and the EMA a common framework. With regulatory clarity in place, the choice now rests on each molecule's chemistry and the cost of new equipment.
Continuous flow manufacturing is a method of producing an API in which materials move through connected equipment without stopping. Pumps feed starting materials into the system at a fixed rate. As the material flows, it passes through each reaction and purification step in sequence. The finished API is collected at the end of the line, while new material keeps entering at the start. This allows a single line to run for long periods, sometimes several months.
In API synthesis, reactions usually run in flow reactors consisting of narrow tubes or coils. Because each tube holds little material, heat dissipates quickly, and the temperature remains stable. Reaction time is precisely set by the flow rate. When a single reaction runs this way, chemists call it flow chemistry.
Continuous flow manufacturing for APIs links several such reactions and their purification steps into one line. Many API processes combine continuous steps with conventional batch steps. ICH Q13's own example runs two reactions continuously, then mills the finished API in batch mode.
Batch and continuous processing differ in how material moves between production steps. In batch mode, a fixed quantity finishes one step completely before moving to the next. In continuous mode, all connected steps run at the same time as material flows through the line. This difference shapes how quality is controlled and how output grows in manufacturing for APIs.
The table below compares continuous manufacturing vs batch manufacturing across the factors that matter most:
| Factor | Batch Manufacturing | Continuous Manufacturing |
|---|---|---|
| How material moves | A fixed quantity completes each step before the next step begins. | Material flows through all connected steps simultaneously. |
| Quality control | Production pauses after key steps so analysts can test intermediates offline. | In-line sensors, such as on-line HPLC, measure quality while the material moves through the line. |
| Off-spec material | The affected batch may need rework or rejection. | The system diverts only the affected portion once a reading drifts outside set limits. |
| Scale-up | Output grows through larger reactors, which often means repeating process studies at each new scale. | Output increases with longer run times or by adding identical lines. The equipment size stays the same throughout. |
| Development data | Small-scale results may not fully predict behavior in larger vessels. | Development runs can use commercial-scale equipment, so data transfers more directly. |
| Reaction safety | Large reaction volumes increase the risk of heat-releasing reactions. | Small reacting volumes make it easier to control the heat. |
| Upfront investment | Lower where batch reactors are already installed. | Higher, due to new equipment and control systems. |
| Best suited to | Low volumes and multiproduct plants. | High, steady volumes and fast or heat-releasing reactions. |
The main benefits of continuous manufacturing for APIs are shorter production time and more consistent quality. Continuous lines also handle hazardous reactions more safely. These gains come from reacting small volumes of material under constant conditions, an approach called process intensification.
Here are the key benefits continuous processing offers API producers:
ICH Q13 is a global guideline that explains what regulators expect from the continuous manufacturing of drug substances and drug products. The International Council for Harmonization adopted it in November 2022, after a four-year drafting process. Each ICH regulatory member then brought Q13 into its own regional rules. The FDA published it as final guidance for industry in March 2023. The EMA's adopted version of ICH Q13 took effect in July 2023.
The ICH Q13 continuous manufacturing guideline covers two product types: chemical entities and therapeutic proteins. It applies to new products, such as new drugs and generics. It also applies when a company converts an existing batch process to continuous operation. To make these principles practical, the guideline pairs its main text with five annexes. Each annex applies the principles to a specific product type or operating scenario.
ICH Q13 has given continuous manufacturing for APIs a defined regulatory path across major markets. Before its adoption, companies often agreed on technical expectations with each agency separately. ICH regulators, including the FDA and EMA, now assess continuous processes against the same guidelines. One process design and control approach can therefore support filings in several regions.
The guideline also answers practical questions that are unique to continuous operation. The first is how to define a batch when material flows without a natural endpoint. Q13 lets companies set batch size by material quantity or by run time at a defined flow rate. Companies can also register a batch size range and adjust output within it without a new filing.
The second question is how to handle material that falls out of specification during a run. Q13 addresses this through residence time distribution, which measures how long material stays in each unit. This timing data lets producers trace affected material and divert only that portion from the batch. Annex V uses worked examples to show which disturbances require diversion.
Most challenges limiting continuous manufacturing for APIs are now practical, because ICH Q13 has clarified the main regulatory expectations. The first hurdle is the existing plant base. Most commercial API plants run multipurpose batch reactors that produce many different molecules. Companies have already invested heavily in this equipment, so replacing it needs a strong business case.
That business case must account for these costs and technical limits:
Because of these limits, the process format is best decided early in pharmaceutical process development. Routes with solid-forming steps often work better as hybrid batch-continuous processes. Fast reactions with sharp heat release or intense mixing needs usually suit flow reactors. Slower reactions with gentle heat profiles run well in batch vessels.
Neuland Laboratories measures both factors through its Process Safety and Engineering Assessment services. Its process safety team uses reaction calorimetry to measure heat release before lab-to-plant transfer. The company's engineers also simulate mixing and heat transfer for plant-scale scenarios. Hazard and operability studies then document risks ahead of scale-up and technology transfer. This evidence helps shape an API manufacturing process that stays safe and consistent at commercial scale.
Assessing hazardous chemistry before choosing a format?
Neuland's process safety team identifies explosive properties and classifies dangerous goods during development. It also evaluates operational hazards such as flammability and static electricity. Talk to Neuland's process safety team about your API's hazard profile today.
The APIs best suited to continuous flow manufacturing combine steady, high demand with fast liquid-phase chemistry. These molecules keep a line running long enough to recoup the cost of the equipment.
Common signs of a good fit include:
Yes, continuous manufacturing is FDA-approved for pharma, with approval granted to each product and its process. The agency reviews the continuous process as part of each drug application. The FDA approved its first drug made on a continuous line in July 2015. By May 2026, an FDA official reported 17 approved drugs that use continuous manufacturing.
Moving an API from batch to continuous manufacturing requires data showing that the new process delivers comparable quality. ICH Q13 asks companies to establish this through a science- and risk-based approach. A typical data package includes:
Continuous manufacturing does not require real-time release testing under ICH Q13. Real-time release testing uses in-process data to confirm quality without separate end-product tests. Companies can still use conventional release testing for a continuous line. If a company proposes real-time release, Q13 expects a backup plan for any lapse in data collection.
